FDA Accepts sNDA for Neratinib Combo for HER2+ Breast Cancer
The FDA has accepted a supplemental new drug application for neratinib for use in combination with capecitabine for the treatment of patients with HER2-positive metastatic breast cancer who have failed at least 2 prior lines of HER2-directed treatments.
Source: OncLive